Is ghrelin the same as growth hormone?

No. Ghrelin is a hormone that stimulates growth hormone release (among other effects). It's called a 'growth hormone secretagogue' because it causes the pituitary to secrete GH.

Can blocking ghrelin help with weight loss?

This is an active area of research. Reducing ghrelin signaling could theoretically reduce appetite and promote weight loss. However, the complexity of appetite regulation means this is not straightforward, and no approved ghrelin-blocking drugs exist for obesity.

Why am I hungry before meals?

Ghrelin levels rise before meals, signaling to the brain that it's time to eat. This preprandial ghrelin rise is a key trigger for meal initiation. Ghrelin then falls after eating, contributing to satiety.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 1 February 2026

Share:X Post LinkedIn

Fat Loss & Metabolic•Updated 2026-02-01•5 min read

What Is Ghrelin? Benefits, Research & Safety

The 'hunger hormone' that stimulates appetite and growth hormone release, with important roles in metabolism and energy balance.

Share:X Post LinkedIn

Also known as:

The Hunger Hormone

Lenomorelin

Growth Hormone Secretagogue

AStrong human evidenceUK: Sold as 'research only' (UK)WADA: Prohibited in sport

UK summary: Endogenous gut hormone — not a medicine but the basis for ghrelin-receptor agonist drug development. This entry is educational background; therapeutic exposure happens through other compounds (GHRPs etc).

Quick Facts

Overview

Ghrelin is a 28-amino acid peptide hormone primarily produced by specialised cells in the stomach lining. It is the only known hormone that stimulates appetite, earning it the nickname "hunger hormone." Ghrelin levels rise before meals and fall after eating, playing a key role in meal initiation and energy homeostasis. Beyond appetite stimulation, ghrelin has multiple biological effects: it stimulates growth hormone release from the pituitary, affects glucose and lipid metabolism, modulates gastrointestinal function, and influences cardiovascular and immune systems. Ghrelin was discovered in 1999 as the endogenous ligand for the growth hormone secretagogue receptor (GHSR, now called the ghrelin receptor). This connected the peptide to both appetite regulation and the growth hormone axis. The understanding that ghrelin drives hunger has made it an attractive target for obesity treatment—blocking ghrelin might reduce appetite and promote weight loss. Conversely, ghrelin agonists could help conditions characterised by poor appetite and wasting (cachexia, anorexia). Ghrelin mimetics are in clinical development for various conditions, though none have achieved widespread approval for appetite modulation.

Evidence standards summary

Ghrelin — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

AStrong human evidenceOverall grade against our evidence grading methodology.

Endogenous gut hormone — not a medicine but the basis for ghrelin-receptor agonist drug development. This entry is educational background; therapeutic exposure happens through other compounds (GHRPs etc).

02Human evidence grade

AStrong human evidenceStrength of evidence from published human trials.

03Preclinical evidence grade

AStrong human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Not approved for therapeutic use. Research compound.
EU: Not approved. Research only.
Notes: Ghrelin itself is not used therapeutically. Ghrelin receptor agonists (like anamorelin) have been studied for cachexia and are approved in some countries (Japan). The ghrelin system remains an active therapeutic target.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

Ghrelin supplements boost appetite.
Anti-ghrelin compounds cause weight loss safely.

07Common internet claims

Sold as bodybuilding 'appetite supplements' or weight-loss 'blockers'.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Ghrelin supplements boost appetite”	E	No	High	Native ghrelin is degraded orally; no evidence-based 'ghrelin supplement' exists.
“Suppressing ghrelin causes weight loss”	C	Limited	Moderate	Mechanistically plausible; ghrelin-targeting weight-loss drugs have not become first-line.

09Safety uncertainty score

Moderate

Safety profile partly characterised; some signals from observational or preclinical data.

10Known adverse signals

Native ghrelin has very short half-life and is degraded orally — 'ghrelin supplements' have no rational mechanism.

11Drug-interaction uncertainty

Moderate

Some interaction data published; check with a prescriber for your specific medicines.

12Anti-doping status

WADA: Prohibited in sportWADA strict-liability framing applies.

13UK legal position

UK: Sold as 'research only' (UK)

Not approved for therapeutic use. Research compound.

14EU legal position

Not approved. Research only.

15What this page cannot tell you

What 'ghrelin supplements' actually contain.
Whether any meaningful effect occurs from oral ghrelin-pathway products.

16Last reviewed

Last reviewed: 1 February 2026

Next review due: 1 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

AStrong human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Ghrelin pharmacology happens through GHRPs / GLP-1 antagonists — not standalone ghrelin.

19Safer alternatives / established care pathways

NHS Tier 2 / 3 weight management for genuine appetite-related weight concerns.
Licensed GLP-1 medicines for clinically appropriate cases.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

What appetite-modulating interventions actually have evidence?
Should appetite changes I'm experiencing be investigated?

Discovery & History

Ghrelin was discovered in 1999 by Masayasu Kojima and colleagues in Japan. They identified it as the endogenous ligand for the growth hormone secretagogue receptor (GHS-R), which had been known since the development of synthetic growth hormone secretagogues. The name "ghrelin" derives from "ghre," a Proto-Indo-European root for "grow," reflecting its growth hormone-releasing activity. The discovery explained how synthetic GH secretagogues like GHRP-6 worked—they mimicked an endogenous signal. The surprising finding was that ghrelin was primarily produced in the stomach, not the brain. This established a gut-brain signaling axis connecting nutritional status to hypothalamic appetite centers. Research quickly revealed ghrelin's potent orexigenic (appetite-stimulating) effects. Ghrelin levels rise before meals (preprandial) and fall after eating, acting as a meal initiation signal. This positioned ghrelin as a potential target for obesity treatment. Studies in conditions like anorexia nervosa, cachexia, and post-surgical patients have explored both the pathophysiology of ghrelin dysregulation and therapeutic potential of ghrelin or ghrelin agonists. The ghrelin-growth hormone connection has also led to interest in ghrelin for age-related conditions, though the complexity of ghrelin biology has made therapeutic development challenging.

Mechanism of Action

Ghrelin acts primarily through the growth hormone secretagogue receptor (GHSR-1a): **GHSR Activation in Hypothalamus** Central effects on appetite: - Activates NPY/AgRP neurons (appetite-stimulating) - Inhibits POMC/CART neurons (appetite-suppressing) - Results in increased hunger and food intake - Affects food reward and motivation **Pituitary Effects** Growth hormone secretagogue activity: - Stimulates GH release from somatotrophs - Works synergistically with GHRH - Contributes to pulsatile GH secretion **Peripheral Effects** Direct effects in various tissues: - Stomach: Regulates gastric motility and acid secretion - Adipose tissue: Effects on lipid metabolism - Liver: Modulates glucose metabolism - Heart: Potential cardioprotective effects **Unique Modification** Ghrelin requires acylation (addition of octanoyl group) for receptor activation: - Acyl-ghrelin is the active form - Des-acyl ghrelin has different (often opposing) effects - Ghrelin O-acyltransferase (GOAT) enzyme is required - This has therapeutic implications **Integration with Other Signals** Ghrelin interacts with leptin and insulin: - Ghrelin and leptin have opposing effects on appetite - Insulin suppresses ghrelin secretion - Complex interplay determines energy balance

Researched Benefits

Based on preclinical and clinical research findings:

1
Potent appetite stimulation
2
Growth hormone release
3
Potential treatment for cachexia and wasting
4
Gastrointestinal motility effects
5
Possible cardioprotective properties
6
Research target for obesity (antagonists) and wasting (agonists)

Claim vs Evidence

How popular claims about Ghrelin stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Ghrelin supplements boost appetite”	E	No	High	Native ghrelin is degraded orally; no evidence-based 'ghrelin supplement' exists.
“Suppressing ghrelin causes weight loss”	C	Limited	Moderate	Mechanistically plausible; ghrelin-targeting weight-loss drugs have not become first-line.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Variable in research; typically microgram amounts IV
Frequency	Variable depending on research application
Duration	Variable
Notes	Ghrelin itself is not used therapeutically due to complexity of administration and effects. Ghrelin receptor agonists are in development for cachexia and other conditions. Research use only.

Administration Routes

Routes studied in research settings (educational only):

Intravenous (research)
Subcutaneous (some studies)
Oral ghrelin agonists in development

Half-Life	Stability
Very short; approximately 10-30 minutes for acyl-ghrelin	Acyl-ghrelin subject to deacylation; requires careful handling

Safety Profile & Known Risks

Commonly Reported Side Effects

Increased appetite and food intake
Effects on glucose metabolism
GI effects
Flushing

Rare Risks & Concerns

Unknown long-term effects of chronic elevation
Potential metabolic consequences
Effects on growth hormone axis

Contraindications

Research compound only—not used therapeutically
Obesity would be a relative contraindication for agonists

UK & EU Regulatory Context

🇬🇧 United Kingdom

Not approved for therapeutic use. Research compound.

🇪🇺 European Union

Not approved. Research only.

Ghrelin itself is not used therapeutically. Ghrelin receptor agonists (like anamorelin) have been studied for cachexia and are approved in some countries (Japan). The ghrelin system remains an active therapeutic target.

Clinical Studies Summary

Diagnostic potential of total serum ghrelin in autoimmune gastritis: A systematic review and meta-analysis.

Although total serum ghrelin levels were not significantly different between patients with AIG and healthy controls, significantly lower levels were observed in patients with moderate-to-severe gastric atrophy. Given the high heterogeneity and limitations of existing studies, the diagnostic utility of serum ghrelin in AIG warrants further investigation.

PLoS One. 2026View on PubMed

The effectiveness of fasting regimens on serum levels of some major weight regulating hormones: a GRADE-assessed systematic review and meta-analysis in randomized controlled trial.

Ethics, consent to participate: Not applicable. Consent for publication: Not applicable.

J Health Popul Nutr. 2025View on PubMed

Relationship between ghrelin and thyroid disease: a meta-analysis.

This systematic review is the first to evaluate the relationship between ghrelin and thyroid disease. Determining the role of ghrelin in thyroid disease will significantly contribute to understand of symptom or pathomechanism.

Front Endocrinol (Lausanne). 2025View on PubMed

Investigating ghrelin and its isoforms in eating disorders: a network meta-analysis.

This meta-analysis highlighted significant differences in the levels of ghrelin and its isoforms across various ED subgroups and HC, emphasizing their potential roles in the pathophysiology of these disorders, in a perspective of potential targeted therapeutic implications.

Prog Neuropsychopharmacol Biol Psychiatry. 2025View on PubMed

The effects of green tea extract supplementation on body composition, obesity-related hormones and oxidative stress markers: a grade-assessed systematic review and dose-response meta-analysis of randomised controlled trials.

Our results suggest that GTE supplementation can attenuate oxidative stress, BM, BMI and BFP, which are thought to negatively affect human health. Moreover, GTE as a nutraceutical dietary supplement can increase TAC and adiponectin.

Br J Nutr. 2024View on PubMed

Peripheral Biomarkers of Anorexia Nervosa: A Meta-Analysis.

Baker was employed by the Equip Health, Inc. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Nutrients. 2024View on PubMed

Registered Trials & Regulatory Status

Registered trials

Currently recruiting

Furthest phase

Phase 4

Approved product

23 of 30 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

Effects of Antagonizing the Ghrelin Receptor on Brain Food Cue Reactivity in Obesity

Status: Active Not Recruiting · 28 participants · University Hospital, Gentofte, Copenhagen

Conditions: Obesity and Overweight

No results postedNCT06845033

Effects of Ghrelin Administration on Motivation

Status: Completed · 24 participants · University Hospital Tuebingen

Conditions: Major Depressive Disorder

No results postedNCT06576440

Effect of Triticum Aestivum on Appetite, Ghrelin, Leptin, Adiponectin Hormonal Axis in Patients With Obesity

PHASE3

Status: Unknown · 38 participants · Coordinación de Investigación en Salud, Mexico

Conditions: Obesity, Leptin Deficiency, Ghrelin

No results postedNCT06496100

RCT of Ghrelin in Stroke Patients

PHASE2

Status: Unknown · 80 participants · Rijnstate Hospital

Conditions: Stroke, Ischemic

No results postedNCT05726240

Effects of Obesity and Intensity of Exercise on Ghrelin Levels

Status: Completed · 40 participants · University of Virginia

Conditions: Obesity, Insulin Resistance, Cardiovascular Risk Factor

No results postedNCT04581980

Unacylated Ghrelin to Improve Functioning in PAD

PHASE2

Status: Completed · 25 participants · Northwestern University

Conditions: Peripheral Artery Disease

Results postedNCT04377126

Physiological Responses to Laparoscopic Sleeve Gastrectomy: Focusing on Ghrelin

Status: Completed · 12 participants · Hvidovre University Hospital

Conditions: Bariatric Surgery

No results postedNCT04055025

Ghrelin Levels in Patients With Protein C Deficiency

N/A

Status: Unknown · 60 participants · University of Aarhus

Conditions: Protein C Deficiency

No results postedNCT04180657

The Effect High Protein-Fiber Diet With Exercise on Acylated Ghrelin and Leptin in Obese Adolescents

Status: Completed · 56 participants · Universitas Diponegoro

Conditions: Weight Loss, Adolescent Obesity

No results postedNCT04377906

Validation of the Concept of the Autoantibodies Directed Against the Neuropeptides Involved in Food Intake Regulation on the Incidental Cases of Eating Disorders

Status: Completed · 211 participants · University Hospital, Rouen

Conditions: Eating Disorder

No results postedNCT03510533

Does Increase in Appetite After Iron Treatment Induced by Ghrelin Hormone

N/A

Status: Completed · 111 participants · HaEmek Medical Center, Israel

Conditions: Anemia

No results postedNCT02734641

Ghrelin and Diastolic Heart Function

N/A

Status: Completed · 60 participants · University of Campania Luigi Vanvitelli

Conditions: Diabetes Mellitus, Type 2, Obesity, Abdominal, Diastolic Dysfunction

No results postedNCT05988346

Adverse event reports (FDA FAERS)

Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

Source: ClinicalTrials.gov and openFDA. Updated automatically.

Looking for Ghrelin?

Source research-grade Ghrelin from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about Ghrelin